{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:25:03Z","timestamp":1792790703467,"version":"4.5.0"},"reference-count":42,"publisher":"Touch Medical Media, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<p>Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care.<\/p>","DOI":"10.17925\/ee.2022.18.1.27","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T12:50:03Z","timestamp":1657975803000},"page":"27","source":"Crossref","is-referenced-by-count":16,"title":["Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes"],"prefix":"10.17925","volume":"18","author":[{"given":"Armaan","family":"Nallicheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Close Concerns, San Francisco, CA, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M","family":"Mahoney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Close Concerns, San Francisco, CA, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna A","family":"Gutow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Close Concerns, San Francisco, CA, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Bellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"R&B Medical Group, Williamsville, NY, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Isaacs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cleveland Clinic, Cleveland, OH, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Heile M, Hollstegge B, Broxterman L, et al. Automated insulin delivery: Easy enough to use in primary care?\n                      Clin Diabetes\n                      . 2020;38:474\u201385.","DOI":"10.2337\/cd20-0050"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Boughton CK, Hovorka R. Automated insulin delivery in adults.\n                      Endocrinol Metab Clin North Am\n                      . 2020;49:167\u201378.","DOI":"10.1016\/j.ecl.2019.10.007"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes.\n                      Diabetes Technol Ther\n                      . 2017;19:155\u201363.","DOI":"10.1089\/dia.2016.0421"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, et al. Safety evaluation of the MiniMed 670G system in children 7-13 years of age with type 1 diabetes.\n                      Diabetes Technol Ther\n                      . 2019;21:11\u20139.","DOI":"10.1089\/dia.2018.0264"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes.\n                      JAMA\n                      . 2016;316:1407\u20138.","DOI":"10.1001\/jama.2016.11708"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Akturk HK, Giordano D, Champakanath A, et al. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes.\n                      Diabetes Obes Metabo\n                      . 2020;22:583\u20139.","DOI":"10.1111\/dom.13933"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): A multicentre, randomised, crossover trial.\n                      Lancet\n                      . 2021;397:208\u201319.","DOI":"10.1016\/S0140-6736(20)32514-9"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Stone MP, Agrawal P, Chen X, et al. Retrospective analysis of 3-month real-world glucose data after the MiniMed 670G system commercial launch.\n                      Diabetes Technol Ther\n                      . 2018;20:689\u201392.","DOI":"10.1089\/dia.2018.0202"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Carlson AL, Sherr JL, Shulman DI, et al. Safety and glycemic outcomes during the MiniMed\u2122advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes.\n                      Diabetes Technol Ther\n                      . 2021;10.","DOI":"10.1089\/dia.2021.0319"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Collyns OJ, Meier RA, Betts ZL, et al. Improved glycemic outcomes with Medtronic MiniMed advanced hybrid closed-loop delivery: Results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes.\n                      Diabetes Care\n                      . 2021;44:969\u201375.","DOI":"10.2337\/dc20-2250"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Nimri R, Grosman B, Roy A, et al. Feasibility study of a hybrid closed-loop system with automated insulin correction boluses.\n                      Diabetes Technol Ther\n                      . 2021;23:268\u201376.","DOI":"10.1089\/dia.2020.0448"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Beato-V\u00edbora PI, Gallego-Gamero F, Ambrojo-L\u00f3pez A. Rapid improvement in time in range after the implementation of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes.\n                      Diabetes Technol Ther\n                      . 2021;23:609\u201315.","DOI":"10.1089\/dia.2021.0037"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes.\n                      N Eng J Med\n                      . 2019;381:1707\u201317.","DOI":"10.1056\/NEJMoa1907863"},{"key":"ref14","unstructured":"Tandem Diabetes Care, Inc. First smartphone app FDA cleared for insulin delivery on both iOS and Android Operating Systems. 2022. Available at: https:\/\/investor.tandemdiabetes.com\/news-releases\/news-release-details\/tandem-diabetes-care-announces-fda-clearance-tslim-x2-insulin-0 (accessed 29 March 2022)."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Breton MD, Kanapka LG, Beck RW, et al. A randomized trial of closed-loop control in children with type 1 diabetes.\n                      N Eng J Med\n                      . 2020;383:836\u201345.","DOI":"10.1056\/NEJMoa2004736"},{"key":"ref16","unstructured":"Business wire. Insulet announces FDA clearance of its Omnipod\u00ae5 automated insulin delivery system, first tubeless system with smartphone control. 2022. Available at: businesswire.com\/news\/home\/20220127006047\/en\/Insulet-Announces-FDA-Clearance-of-its-Omnipod%C2%AE-5-Automated-Insulin-Delivery-System-First-Tubeless-System-with-Smartphone-Control (accessed 29 March 2022)."},{"key":"ref17","unstructured":"Our approach to innovation. Available at: www.omnipod.com\/hcp\/products\/innovation (accessed 30 November 2021)."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Boughton CK, Hovorka R. New closed-loop insulin systems.\n                      Diabetologia\n                      . 2021;64:1007\u201315.","DOI":"10.1007\/s00125-021-05391-w"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Cappon G, Vettoretti M, Sparacino G, Facchinetti A. Continuous glucose monitoring sensors for diabetes management: A review of technologies and applications.\n                      Diabetes Metab J\n                      . 2019;43:383\u201397.","DOI":"10.4093\/dmj.2019.0121"},{"key":"ref20","unstructured":"Global News Wire. Medtronic secures CE mark for MiniMed\u2122 780G advanced hybrid closed loop system designed to further simplify type 1 diabetes management. Available at: www.globenewswire.com\/news-release\/2020\/06\/11\/2046922\/0\/en\/Medtronic-Secures-CE-Mark-for-MiniMed-780G-Advanced-Hybrid-Closed-Loop-System-Designed-to-Further-Simplify-Type-1-Diabetes-Management.html?msclkid=4163240cd00b11eca62cbb6cf68489ad (Accessed on 17 May 2022)."},{"key":"ref21","unstructured":"Medtronic plc. Available at: www.medtronicdiabetes.com\/about-medtronic-innovation\/innovation-pipeline?msclkid=11d4845ad00b11ec8d40acd803c824c2 (Accessed on 17 May 2022)."},{"key":"ref22","unstructured":"MiniMed\u2122780G system with Guardian\u2122 4 sensor. Available at: www.medtronic-diabetes.co.uk\/insulin-pump-therapy\/minimed-780g-system (accessed 30 November 2021)."},{"key":"ref23","unstructured":"ClinicalTrials.gov. Home use of MD-logic automated insulin delivery system: Safety and efficacy. ClinicalTrials.gov Identifier: NCT03040414. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03040414 (accessed 27 March 2022)."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Breton MD, Kovatchev BP. One year real-world use of the control-IQ advanced hybrid closed-loop technology.\n                      Diabetes Technol Ther\n                      . 2021;23:601\u20138.","DOI":"10.1089\/dia.2021.0097"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Forlenza GP, Ekhlaspour L, Breton M, et al. Successful at-home use of the tandem Control-IQ artificial pancreas system in young children during a randomized controlled trial.\n                      Diabetes Technol Ther\n                      . 2019;21:159\u201369.","DOI":"10.1089\/dia.2019.0011"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ekhlaspour L, Schoelwer MJ, Forlenza GP, et al. Safety and performance of the Tandem T:slim X2 with Control-IQ automated insulin delivery system in toddlers and preschoolers.\n                      Diabetes Technol Ther\n                      . 2021;23:384\u201391.","DOI":"10.1089\/dia.2020.0507"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Forlenza GP, Li Z, Buckingham BA, et al. Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial.\n                      Diabetes Care\n                      . 2018;41:2155\u201361.","DOI":"10.2337\/dc18-0771"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Howard Zisser, Lois Jovanovic. OmniPod insulin management system: Patient perceptions, preference, and glycemic control.\n                      Diabetes Care\n                      . 2006;29:2175.","DOI":"10.2337\/dc06-0986"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Brown SA, Forlenza GP, Bode BW, et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes.\n                      Diabetes Care\n                      . 2021;44:1630\u201340.","DOI":"10.2337\/figshare.14423636.v2"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Forlenza GP, Buckingham BA, Brown SA, et al. First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes.\n                      Diabetes Technol Ther\n                      . 2021;23:410\u201324.","DOI":"10.1089\/dia.2020.0546"},{"key":"ref31","unstructured":"How to get started with DIY \u201cArtificial Pancreas\u201d systems. 2021. Available at: www.diabettech.com\/looping-a-guide\/ (accessed 30 November 30)."},{"key":"ref32","unstructured":"Welcome to Nightscout. Available at: www.nightscout.info\/ (accessed 27 April 2022)."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Asarani NA, Reynolds AN, Elbalshy M, et al. Efficacy, safety, and user experience of DIY or open-source artificial pancreas systems: A systematic review.\n                      Acta Diabetol\n                      . 2020;58:539\u201347.","DOI":"10.1007\/s00592-020-01623-4"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Burnside M, Lewis D, Crocket H, et al. CREATE (Community deRivEd AutomaTEd insulin delivery) trial. Randomised parallel arm open label clinical trial comparing automated insulin delivery using a mobile controller (AnyDANA-loop) with an open-source algorithm with sensor augmented pump therapy in type 1 diabetes.\n                      J Diabetes Metab Disord\n                      . 2020;19:1615\u201329.","DOI":"10.1007\/s40200-020-00547-8"},{"key":"ref35","unstructured":"Australian New Zealand Clinical Trials Registry. Randomised parallel arm open label clinical trial comparing automated insulin delivery using an open-source algorithm (AnyDANA-loop), with sensor augmented pump therapy in type 1 diabetes. Registration Number: ACTRN12620000034932. Available at: anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=378711&isReview=true (accessed 27 March 2022)."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Lum JW, Bailey RJ, Barnes-Lomen V, et al. A real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system.\n                      Diabetes Technol Ther\n                      . 2021;23:367\u201375.","DOI":"10.1089\/dia.2020.0535"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Messer LH, Berget C, Vigers T, et al. Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months.\n                      Pediatric Diabetes\n                      . 2020;21:319\u201327.","DOI":"10.1111\/pedi.12971"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Messer LH, Berget C, Forlenza GP. A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm.\n                      Diabetes Technol Ther\n                      . 2019;21:462\u20139.","DOI":"10.1089\/dia.2019.0105"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger J, Reichel A, Siegmund T, Ziegler R. Clinical recommendations for the use of the ambulatory glucose profile in diabetes care.\n                      J Diabetes Sci Technol\n                      . 2020;14:586\u201394.","DOI":"10.1177\/1932296819883032"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range.\n                      Diabetes Care\n                      . 2019;42:1593\u2013603.","DOI":"10.2337\/dci19-0028"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Greenwood DA, Howell F, Scher L, et al. A framework for optimizing technology-enabled diabetes and cardiometabolic care and education: The role of the diabetes care and education specialist.\n                      Diabetes Educ\n                      . 2020;46:315\u201322.","DOI":"10.1177\/0145721720935125"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Castellanos LE, Balliro CA, Sherwood JS, et al. Performance of the insulin-only iLet bionic pancreas and the bihormonal iLet using dasiglucagon in adults with type 1 diabetes in a home-use setting.\n                      Diabetes Care\n                      . 2021;44:e118\u201320.","DOI":"10.2337\/dc20-1086"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/diabetes\/journal-articles\/review-of-automated-insulin-delivery-systems-for-type-1-diabetes-and-associated-time-in-range-outcomes\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:59:38Z","timestamp":1764745178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchendocrinology.com\/diabetes\/journal-articles\/review-of-automated-insulin-delivery-systems-for-type-1-diabetes-and-associated-time-in-range-outcomes\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["EE.2022.18.1.27"],"URL":"https:\/\/doi.org\/10.17925\/ee.2022.18.1.27","relation":{},"ISSN":["2752-5457"],"issn-type":[{"value":"2752-5457","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}